|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:alternativeTo
|
gptkb:Zostavax
|
|
gptkbp:approvalYear
|
2017
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:J07BK02
|
|
gptkbp:contains
|
gptkb:AS01B_adjuvant
recombinant varicella zoster virus glycoprotein E
|
|
gptkbp:contraindication
|
severe allergic reaction to any component
|
|
gptkbp:doseInterval
|
2 to 6 months apart
|
|
gptkbp:dosingSchedule
|
two doses
|
|
gptkbp:effect
|
over 90% effective in preventing shingles
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Shingrix
|
|
gptkbp:indication
|
adults aged 50 and older
|
|
gptkbp:manufacturer
|
GlaxoSmithKline
|
|
gptkbp:notLiveVaccine
|
true
|
|
gptkbp:pregnancyCategory
|
not recommended during pregnancy
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fatigue
headache
muscle pain
pain at injection site
|
|
gptkbp:storage
|
2°C to 8°C
|
|
gptkbp:usedFor
|
prevention of herpes zoster
prevention of shingles
|
|
gptkbp:WHOStatus
|
included in WHO Model List of Essential Medicines
|
|
gptkbp:bfsParent
|
gptkb:varicella-zoster_virus
gptkb:GSK
gptkb:Zostavax
gptkb:shingles_(herpes_zoster)
|
|
gptkbp:bfsLayer
|
6
|